Comparative study of SQ 18 506 with other nitroheterocyclic compounds on experimental Chagas' disease.
The activity of the 5-nitrovinylfuran, SQ 18 506, is compared in vivo and in vitro with lampit (a 5-nitrofuran), Ro 7-1051 (a 2-nitroimidazole) and metronidazole (a 5-nitroimidazole). The order of activities on a weight basis was: SQ 18 506 greater than lampit greater than Ro 7-1051 greater than metronidazole. Concern about possible mutagenicity and carcinogenicity, however, has precluded the use of SQ 18 506 in clinical trials.
D013184:5-Amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D014355:Chagas Disease / Q000188:drug therapy*; D046508:Culture Techniques; D004353:Drug Evaluation, Preclinical; D005260:Female; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D051379:Mice; D008805:Mice, Inbred A; D009581:Nitrofurans / Q000627:therapeutic use*; D009593:Nitroimidazoles / Q000627:therapeutic use
D009581:Nitrofurans; D009593:Nitroimidazoles; D008795:Metronidazole; D013184:5-Amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole